Close

Not a member yet? Register now and get started.

lock and key

Sign in to your account.

Account Login

Forgot your password?

Biotechnology  // Browsing posts in Biotechnology

Jun 24 2016 Biotechnology, Healthcare

NVDQ’s DermACELL On Track to Achieve 2016 Sales Goal of $10 Million

Research Question: Will Novadaq grow DermACELL sales to $10 million in 2016 and $50 million or more by 2018? Companies: AGN, IART, JNJ, MDXG, NVDQ, NVS, OSIR By: David Franklin Click here to download the report (.pdf)   Summary of Findings DermACELL, an acellular dermal matrix (ADM) tissue that is used primarily in breast reconstruction, is likely […]

Read more...

Novadaq Idea Proposal

Novadaq Idea Proposal

Will Novadaq successfully grow DermACELL sales to $50 million or more by 2018? Report Available: June 23, 2016   Blueshift’s initial research shows sales of NVDQ’s DermACELL, its acellular dermal matrix (ADM) product used primarily in breast reconstruction, increasing as it becomes part of the company’s fastest growing segment. Management expects it to reach about $10 […]

Read more...

Buprenorphine Opioid Addiction Treatment Idea Proposal

Buprenorphine Opioid Addiction Treatment Idea Proposal

Will long acting implantable and injectable buprenorphine become widely adopted for opioid addiction treatment? Report Available: April 8, 2016   Blueshift’s initial research shows that addiction to opioids has skyrocketed to the point of being an epidemic. Current available treatment options face numerous challenges including frequent dosing, poor adherence, high incidence of relapse, and misuse. […]

Read more...

Exact Sciences’ Cologuard the Preferred Test for Patients Refusing Colonoscopy (EXAS)

Research Question: Will Exact Sciences’ Cologuard become physician’s screening test of choice for colon cancer? Companies: ABT, BDX, BIOC, BSX, CHEK, CPHD, DGX, EXAS, FMI, GIVN, GSK, IRWD, RHHBY By: David Franklin Click here to download the report (.pdf)   Summary of Findings Exact Sciences Corp.’s (EXAS) Cologuard has high clinical value, but it is unlikely […]

Read more...

Exact Sciences Whisper

Exact Sciences Whisper

Research Question: Will Exact Sciences’ Cologuard become the colon cancer screening test of choice for physicians? Report Available: August 14, 2015   Blueshift’s initial research shows EXAS’s Cologuard, a non-invasive test for colon cancer, is monetizing at a significant rate following FDA approval and an increased sales staff. But some physicians argue the screener should not be […]

Read more...

Well-Received Zarxio Will Pave Way to Eventual Wide Biosimilar Adoption

Research Question: Will Sandoz’s (Novartis) Zarxio, the first biosimilar approved by the FDA, be widely adopted by the medical and managed care community and pave the way for future biosimilars? Companies: AMGN, BOM:500359, EPRS, ESRX, HSP, KOSDAQ:068270, NVS, MRK, PFE By: Linda Richards Click here to download the report (.pdf)   Summary of Findings Adoption of […]

Read more...

Aug 11 2014 Biotechnology, Healthcare

Questcor’s Acthar Gel Sales Will Be Challenged by Tightened Guidelines

Research Question: Will Questcor’s growth be derailed by UnitedHealth’s, Cigna’s and Aetna’s limited reimbursement policy for Acthar Gel? Companies: AET, AMGN, CI, GILD, MNK, QCOR, RHHBY, UNH By: David Franklin Click here to download the report (.pdf)   Summary of Findings Questcor Pharmaceuticals Inc.’s (QCOR) Acthar Gel, which represents 95% of the company’s total sales, will face challenges […]

Read more...

Jul 16 2014 Biotechnology, Healthcare

Aegerion’s Juxtapid Likely to See Limited Sales Improvement

Research Question: Is the leveling off of Aegerion’s Juxtapid sales permanent, or will growth return? Companies: AEGR, AMGN, ISIS, PFE, REGN, SNY By: David Franklin Click here to download the report (.pdf)   Summary of Findings Aegerion Pharmaceuticals Inc.’s (AEGR) orphan drug Juxtapid, which treats the extremely rare HoFH lipid disorder, likely will experience only a limited sales […]

Read more...

Illumina Still Leads in Challenging DNA Sequencing Market (ILMN)

Research Question: How well is Illumina positioned to face DNA sequencing research funding issues, overcapacity concerns, and next-generation technology challenges? By: David Franklin Companies: DGX, ETR:QIA/QGEN, FRA:RH05,  GNOM, ILMN, LH, LIFE, PACB, PKI, SQNM Click here to download the report (.pdf)   Summary of Findings The large-scale and next-gen sequencer markets are facing short-term challenges. Funding shifts […]

Read more...

Elan’s AD Drugs Hold Potential, MS Drug Tysabri Mired by Rep (PRGO)

Research Questions: Will ELND005 and bapineuzumab (bapi), Elan’s pipeline treatments for Alzheimer’s disease, receive FDA approval and become blockbusters? Also, will the availability of a blood test and a treatment for the John Cunningham virus lead to increased sales for the multiple sclerosis drug Tysabri? By: David Franklin Companies: BAX, BIIB, ELN, EPA:SAN/SNY, ETR:BAYN/BAYRY, FRX, JNJ, […]

Read more...